Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Hyperuricemia: early-phase trial registry

2 of 12 indexed Hyperuricemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 2 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Hyperuricemia: 12 US clinical trials tracked, 2 recruiting.

Hyperuricemia is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Arthrosi Therapeutics, running 3 of these trials.

Enrollment posture brief

Registry condition hyperuricemia

OPEN 2 | RECR 17% | LATE 3 | EARLY 8 | RANK #1429 | SPON 3

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Hyperuricemia (this)17%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Hyperuricemia

Hyperuricemia lists 2 open slots (17% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hyperuricemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hyperuricemia is recruiting below its size-band peers.

    2 of 12 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hyperuricemia research.

    Arthrosi Therapeutics accounts for 3 of 12 trials (25%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Hyperuricemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 32 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.

  4. Hyperuricemia research is mostly interventional.

    12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 23Phase 32Phase 41

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 1 60 participants

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

Novo Nordisk A/S

NCT06859073

RECRUITING Phase 2 25 participants

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

Arthrosi Therapeutics

NCT07116746

ACTIVE NOT RECRUITING Phase 3 750 participants

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Arthrosi Therapeutics

NCT06846515

ACTIVE NOT RECRUITING Phase 3 750 participants

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Arthrosi Therapeutics

NCT06439602

ACTIVE NOT RECRUITING Phase 1 32 participants

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

Shanton Pharma Pte.

NCT06729853

COMPLETED NA 43 participants

The Diet Gout Trial

Johns Hopkins University

NCT03569020

COMPLETED Phase 2 34 participants

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

University of Missouri-Columbia

NCT03648996

COMPLETED Phase 4 27 participants

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

University of California, San Francisco

NCT02956278

COMPLETED Phase 1 24 participants

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

LG Chem

NCT03927677

COMPLETED Phase 1 24 participants

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

LG Chem

NCT04139824

COMPLETED Phase 1 20 participants

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia

Urica Therapeutics

NCT06056570

COMPLETED Phase 2 20 participants

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

BioCryst Pharmaceuticals

NCT01407874

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 3
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Hyperuricemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
AR882 75 mg Drug
3 trials
Xanthine Oxidase Inhibitor Drug
2 trials
AR882 50 mg Drug
2 trials
Allopurinol Drug
2 trials
nonsteroidal anti-inflammatory drug Drug
1 trials
Low-fructose, hypocaloric Other
1 trials
Low-fructose diet, isocaloric Other
1 trials

US sites by state

Facility locations filed on Hyperuricemia trials. A trial with sites in several states counts in each.

Florida 6 trials
Texas 5 trials
California 5 trials
Arizona 3 trials
Alabama 3 trials
Maryland 2 trials
Colorado 2 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hyperuricemia page

12 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperuricemia condition card totals 12 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.